Why the Hepatology History Is Different
Liver disease is frequently silent until decompensation. By the time jaundice, ascites, or encephalopathy appear, significant fibrosis has often already occurred. A thorough, targeted history is your most powerful early detection tool — and it requires probing areas that the standard systems review underemphasizes.
Alcohol: Quantify, Don't Just Screen
Asking "do you drink?" is insufficient. You need quantity, frequency, duration, and type. Use standardized tools where appropriate:
- AUDIT-C: Three-question screen for hazardous or harmful alcohol use. A score ≥3 in women or ≥4 in men warrants further assessment.
- CAGE: Cut down, Annoyed, Guilty, Eye-opener. Validated for identifying alcohol use disorder.
- Quantify in standard drinks per week (1 standard drink = 14g ethanol). Heavy use: >7 drinks/week in women, >14 drinks/week in men.
- Ask about pattern: daily drinking vs. binge drinking carry different risks.
- Explore timeline: duration of heavy use correlates with fibrosis risk.
Medications and Supplements: Ask Specifically
Drug-induced liver injury (DILI) is underrecognized because patients do not volunteer supplement use. You must ask explicitly:
- All prescription medications, including dose and duration
- Over-the-counter analgesics — acetaminophen is the most common cause of acute liver failure in the US. Ask about total daily dose across all products.
- Herbal and dietary supplements (e.g., green tea extract, kava, pyrrolizidine alkaloids)
- Illicit drug use, especially anabolic steroids and injectable drugs (risk for viral hepatitis)
- Recent new medications started in the past 3–6 months (DILI can have a delayed presentation)
Viral Hepatitis Risk Assessment
Hepatitis B and C remain leading causes of cirrhosis and HCC globally. A targeted history should include:
- Birth country (HBV endemic regions: sub-Saharan Africa, Southeast and East Asia)
- Birth year 1945–1965 (HCV birth cohort — universal screening recommended)
- IV drug use, past or present, even a single episode
- High-risk sexual behavior, history of STIs
- Blood transfusion prior to 1992 (HCV screening not yet universal)
- Healthcare worker exposures, tattoos, piercings
Metabolic Risk Factors
Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is now the most prevalent liver disease in the US. Identify:
- Type 2 diabetes or insulin resistance
- Obesity (BMI >30) or central adiposity
- Hypertriglyceridemia, hypertension
- History of bariatric surgery (altered drug metabolism)
- Hypothyroidism (associated with MASLD)
Family History
Hereditary liver diseases are underdiagnosed. Ask specifically about:
- Hemochromatosis (HFE gene mutations — most common genetic liver disease in people of Northern European ancestry)
- Wilson's disease (autosomal recessive; presents in young patients with liver disease ± neuropsychiatric symptoms)
- Alpha-1 antitrypsin deficiency
- Primary biliary cholangitis or primary sclerosing cholangitis (autoimmune; may have family clustering)
- Liver or biliary cancers in relatives
Review of Systems: Symptoms That Suggest Advanced Disease
Ask about symptoms that suggest portal hypertension or hepatic decompensation:
- Abdominal distension (ascites)
- Confusion, sleep disturbances, personality change (hepatic encephalopathy)
- Hematemesis or melena (variceal bleeding or portal hypertensive gastropathy)
- Jaundice or scleral icterus
- Easy bruising, prolonged bleeding (coagulopathy)
- Fatigue, pruritus, dark urine, pale stools (cholestatic disease)